# Keith T. Flaherty

Source: https://onco.cc/people/keith-flaherty/  
OnCo record `keith-flaherty` (Person). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Led the first trials of BRAF inhibition in melanoma and chairs the NCI-MATCH precision medicine trial.

## Summary

Keith T. Flaherty is Director of Clinical Research at the Mass General Cancer Center. He is a melanoma oncologist known for leading the first trials of BRAF inhibition, as first author of the 2010 vemurafenib study, and for the dabrafenib plus trametinib combination work that followed. His selected papers report inhibition of mutated, activated BRAF in metastatic melanoma and combined BRAF and MEK inhibition in BRAF V600-mutant melanoma. He co-chairs the NCI-MATCH precision medicine trial and continues to work on small-molecule kinase inhibitors.

## Fields

- Kind: Person
- Last checked: 2026-09-08
- Role: Director of Clinical Research, Mass General Cancer Center
- Specialisms: Melanoma; BRAF and MEK inhibitors; Precision oncology trials

## Sources

- MGH profile: https://www.massgeneral.org/doctors/16888/keith-flaherty
- PubMed: https://pubmed.ncbi.nlm.nih.gov/?term=Flaherty%20KT%5BAuthor%5D

## Connected records

- cancers: [BRAF V600-mutant melanoma](https://onco.cc/cancers/braf-v600-melanoma/), [Melanoma](https://onco.cc/cancers/melanoma/)
- technologies: [Small-molecule kinase inhibitors](https://onco.cc/technologies/kinase-inhibitors/)
- targets: [BRAF](https://onco.cc/targets/braf/)
- drugs: [Dabrafenib + trametinib](https://onco.cc/drugs/dabrafenib-trametinib/), [Vemurafenib](https://onco.cc/drugs/vemurafenib/)
- institutions: [Massachusetts General Hospital Cancer Center](https://onco.cc/institutions/mgh/)
- terms: [Master protocol (platform, basket and umbrella trials)](https://onco.cc/terms/master-protocol/)
- trials: [COMBI-d](https://onco.cc/trials/combi-d/), [NCI-MATCH (EAY131)](https://onco.cc/trials/nci-match/)

---
JSON: https://onco.cc/api/v1/entities/keith-flaherty.json